17 results
6-K
EX-4.41
FENC
Fennec Pharmaceuticals Inc
9 Aug 06
Adherex Reports Second Quarter 2006 Financial Results
12:00am
indications in all dosage forms and combinations, formulations, presentations, line extensions and package configurations in all countries of the Territory … Eniluracil and Products for all indications in all dosage forms and combinations, formulations, presentations, line extensions and package configurations
8-K
EX-99.1
FENC
Fennec Pharmaceuticals Inc
16 Oct 13
Adherex Announces Updated Guidance for Sodium Thiosulfate (STS) Results
12:00am
for public disclosure. "Pending the outcome of our analysis of the final study results, Adherex plans to meet with the FDA to agree on acceptable data package
6-K
FENC
Fennec Pharmaceuticals Inc
22 Jul 05
Current report (foreign)
12:00am
, formulations, presentations, line extensions and package configurations in all countries of the Territory in which there is a Valid Claim of the GGL Patents … , presentations, line extensions and package configurations in all countries of the Territory in which there is a Valid Claim of the GGL Patents, Adherex Patents
8-K
EX-10.1
FENC
Fennec Pharmaceuticals Inc
21 Mar 24
Fennec Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize PEDMARQSI in Europe, Australia, and New Zealand
4:02pm
University and Adherex, Inc. dated February 20, 2013 (as amended from time to time).
“Package” means to package and label the Product for its promotion … to the Specifications, therapeutic indications, Packaging, labelling, package insert or shipping container or sizes of the Product that is delivered
6-K
EX-99.3
7jpoeikao5pyd
31 Mar 06
Current report (foreign)
12:00am
DEF 14A
67fwsevgi4nfht3 iw
3 Apr 07
Definitive proxy
12:00am
424B3
i2rq rkiq5x4v
14 Feb 11
Prospectus supplement
12:00am
S-1/A
xe3gcukb
9 Feb 11
IPO registration (amended)
12:00am
- Prev
- 1
- Next